Cristina Churruca
A5034608715- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Endometrial and Cervical Cancer Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- Renal cell carcinoma treatment
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Oral health in cancer treatment
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- CRISPR and Genetic Engineering
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- DNA Repair Mechanisms
- Chromatin Remodeling and Cancer
- Lung Cancer Research Studies
- Cancer-related molecular mechanisms research
Biogipuzkoa Health Research Institute
2011-2024
Donostia Unibertsitate Ospitalea
2020-2023
Complejo Hospitalario Universitario de Santiago
2011
Complexo Hospitalario Universitario A Coruña
2011
Hospital Son Llatzer
2011
Hospital de Mataró
2011
Consorci Sanitari de Terrassa
2011
Hospital Clínico San Carlos
2011
Hospital General Universitario Morales Meseguer
2011
Hospital Arnau de Vilanova
2011
PURPOSE Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity across multiple cancers, LGSOC. METHODS This 2:1 randomized binimetinib (45 mg twice daily) versus physician’s choice (PCC). Eligible patients had recurrent measurable LGSOC after ≥ 1 prior...
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
ObjectiveTo assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy.MethodsPRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled newly diagnosed advanced OC responded to platinum-based chemotherapy. Patients were randomized (2:1) or placebo once daily 28-day cycles until disease progression, intolerable toxicity, death. HRQoL was assessed a prespecified secondary end point using responses the...
Importance RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) these genes associated with an increased risk of ovarian breast cancer. Understanding the recombination deficiency (HRD) status tumors from patients germline PVs RAD51C/D could guide therapeutic decision-making improve survival. Objective To characterize clinical tumor characteristics PV carriers, including evaluation HRD status. Design, Setting, Participants This...
Abstract Purpose: We present the results of a post hoc tumor tissue analysis from phase 3 MILO/ENGOT-ov11 study (NCT01849874). Patients and Methods: Mutation/copy-number was performed on obtained pre-randomization. The Kaplan–Meier method used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, binary logistic regression were test associations between mutation status outcomes, including PFS response by local RECIST 1.1. Results: enrolled 341 patients,...
Abstract Purpose To obtain reference norms of EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L, based on a population Spanish non-metastatic breast cancer patients at diagnosis 2 years after, according to relevant demographic clinical characteristics. Methods Multicentric prospective cohort study including consecutive women aged ≥ 18 with incident from April 2013 May 2015. Health-related quality life (HRQoL) questionnaires were administered between beginning the therapy, after. HRQoL differences age,...
Patient registries linked to biorepositories constitute a valuable asset for clinical and translational research in oncology. The Spanish Group of Ovarian Cancer Research (GEICO), collaboration with the Biobank Network (RNBB), has developed multicentre, multistakeholder, prospective virtual registry (VCR) associated biobanks collection real-world data biological samples gynaecological cancer patients. This collaborative project aims promote by providing broad access high-quality biospecimens...
<h3>Introduction/Background</h3> The efficacy and safety evidence of dostarlimab monotherapy in patients with MisMatch Repair deficient/MicroSatellite Instability-High (dMMR/MSI-H) endometrial cancer (EC) who progressed during or after a platinum-containing regimen, comes from the analysis 143 were enrolled phase I clinical trial (GARNET). Therefore, assessing real-world scenario is highly relevant. <h3>Methodology</h3> GEICO 120/DORA multicentre, retrospective, observational study,...
<p>Supplementary Tables and Figures</p>
<p>Supplementary Tables and Figures</p>
<div>Abstract<p>Purpose: We present the results of a post-hoc tumor tissue analysis from phase 3 MILO/ENGOT-ov11 study (NCT01849874). Experimental Design: Mutation/copy number was performed on obtained pre-randomization. Kaplan-Meier method used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were test associations between mutation status outcomes, including PFS response by local RECIST 1·1. Results:...
e15590
6051 Background: Niraparib improves progression-free survival (PFS) in pts with newly diagnosed AOC after complete or partial response to first-line, platinum-based chemotherapy. In the PRIMA/ENGOT-OV26/GOG-3012 (PRIMA) trial, were treated a fixed starting dose (FSD) of 300 mg QD until protocol amendment introduced individualized (ISD) regimen: 200 for baseline bodyweight (BW) < 77 kg and/or platelet count (PC) 150,000/µL, BW ≥77 and PC ≥150,000/µL. Here, we developed population...
5554 Background: Early stage ovarian cancer (ESOC) represents 10-15% of all Ovarian Cancer (OC) cases and most frequent ESOC substage (IC) has undergone major changes in FIGO 2014 staging. Methods: A centralized prospective registry (I-IIb) patients treated at GEICO (Spanish Group Research) centers was initiated on January 1998 updated up to November 2014. We aim prospectivley explore both the robustness role ascites terms prognosis. analyze IA-IB (1), IC1+IC2 (2), IC3 citology positive...
The association of ifosfamide with cisplatin and 5-fluorouracil for the management advanced squamous cell carcinoma head neck was assessed in this trial. Ifosfamide given initially to 12 patients combination standard fixed doses 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, 4. Two died neutropenia severe infection, authors recruited seven more who were treated a lower dose ifosfamide, 800 One infection. Three complete remission observed 18 evaluable efficacy. study closed early because...
<h3>Introduction</h3> Niraparib is a poly(ADP-ribose) polymerase inhibitor approved for treatment in heavily pretreated patients and maintenance of with newly diagnosed or recurrent ovarian cancer following response to platinum-based chemotherapy. Here we report safety patient-reported outcomes (PROs) the overall population subgroups from PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016). <h3>Methods</h3> This double-blind, placebo-controlled, phase 3 study randomized 733 patients. Patients received...
<h3>Introduction/Background*</h3> In the ENGOT-OV16/NOVA trial, niraparib demonstrated a significantly longer PFS in patients (pts) with recurrent platinum-sensitive ovarian cancer (PSOC) vs placebo as maintenance therapy, regardless of gBRCA/HRD status. Niraparib obtained EU approval 2017 and an expanded access program (EAP) was initiated. <h3>Methodology</h3> A retrospective study therapy conducted within Spanish EAP, at 57 hospitals. Niraparib's safety, dose adjustments, effectiveness...